Pub Date : 2026-04-01Epub Date: 2026-02-12DOI: 10.1016/j.idnow.2026.105258
Capucine RICHARD , Sylvain GAUTIER , Pierre BOISSON DE CHAZOURNES , Karim JAFFAL , Ségolène PERRINEAU , Valérie SIVADON TARDY , Cyril CHARRON , Nicolas MANSENCAL , Aurélien DINH , Marion PÉPIN , on behalf of the endocarditis team of A. Paré Hospital
Background
Infective endocarditis (IE) is a rare but severe disease with high morbidity and mortality, increasingly affecting older adults. Data on antibiotic tolerance in this population remain limited.
Methods
We conducted a hospital network cohort study including all patients over 65 years old. diagnosed with IE between May 2016 and August 2024 in the greater Paris area. Antibiotic-related adverse events (AEs) were systematically collected, within six months of follow-up.
Results
Among 83 patients (median age: 84 years), 21 (25.3%) experienced at least one AE. Patients with AEs had longer hospital stays but similar age, autonomy, and in-hospital outcomes compared to those without AEs. Cognitive impairment was significantly associated with a higher risk of AEs, particularly in patients aged ≥ 75 years. Streptococcal IE was less frequently associated with AEs. Most AEs were biological abnormalities or clinical events, mainly involving amoxicillin and cefazolin.
Conclusions
Age alone did not markedly affect antibiotic tolerance.
{"title":"Antibiotic tolerance and safety in infective endocarditis: A focus on older patients","authors":"Capucine RICHARD , Sylvain GAUTIER , Pierre BOISSON DE CHAZOURNES , Karim JAFFAL , Ségolène PERRINEAU , Valérie SIVADON TARDY , Cyril CHARRON , Nicolas MANSENCAL , Aurélien DINH , Marion PÉPIN , on behalf of the endocarditis team of A. Paré Hospital","doi":"10.1016/j.idnow.2026.105258","DOIUrl":"10.1016/j.idnow.2026.105258","url":null,"abstract":"<div><h3>Background</h3><div>Infective endocarditis (IE) is a rare but severe disease with high morbidity and mortality, increasingly affecting older adults. Data on antibiotic tolerance in this population remain limited.</div></div><div><h3>Methods</h3><div>We conducted a hospital network cohort study including all patients over 65 years old. diagnosed with IE between May 2016 and August 2024 in the greater Paris area. Antibiotic-related adverse events (AEs) were systematically collected, within six months of follow-up.</div></div><div><h3>Results</h3><div>Among 83 patients (median age: 84 years), 21 (25.3%) experienced at least one AE. Patients with AEs had longer hospital stays but similar age, autonomy, and in-hospital outcomes compared to those without AEs. Cognitive impairment was significantly associated with a higher risk of AEs, particularly in patients aged ≥ 75 years. Streptococcal IE was less frequently associated with AEs. Most AEs were biological abnormalities or clinical events, mainly involving amoxicillin and cefazolin.</div></div><div><h3>Conclusions</h3><div>Age alone did not markedly affect antibiotic tolerance.</div></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"56 3","pages":"Article 105258"},"PeriodicalIF":2.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146172905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-14DOI: 10.1016/j.idnow.2026.105263
Maria Arango-Uribe, Rotem Keynan, Zipporah Gitau, Camilo Suarez-Ariza, Angela Copete, Mariana Herrera, Camila Oda, Ameeta E Singh, Stuart Skinner, Cara Spence, Lauren J MacKenzie, Ken Kasper, Laurie Ireland, Jared Bullard, David Alexander, Diana Marin, Lucelly Lopez, Margaret Haworth-Brockman, Yoav Keynan, Zulma Vanessa Rueda
Introduction: Chlamydia trachomatis is the most commonly encountered sexually transmitted infection. Our objective was to describe the evolution of chlamydia incidence rates in Alberta, Saskatchewan, and Manitoba as compared to Canada overall, from 1991 to 2022.
Methods: We conducted an ecological study, collecting data on chlamydia infection from publicly available reports throughout Canada, laying special emphasis on Alberta, Saskatchewan, and Manitoba. As variables, we used: Chlamydia incidence rate per 100,000 inhabitants, stratified by sex, age group, ethnicity, province, and year.
Results: In 1991, chlamydia incidence in Alberta (265.0/100,000), Saskatchewan (328.2/100,000), and Manitoba (410.2/100,000) largely exceeded the nationwide rate (164.0/100,000). Incidence subsequently increased dramatically, peaking between 2013 and 2019 (Canada overall: 335.1/100,000; Alberta: 399.9/100,000; Saskatchewan: 534.6/100,000; Manitoba: 604.5/100,000). Females aged 20-29 years accounted for 61.6% of the cases, while incidence in individuals aged 30-39 pronouncedly increased. Coinfection rates with Neisseria gonorrhoeae increased in Alberta (1998-2006) from 2.1% to 5.2% and decreased in Manitoba (2004-2012) from 14.8% to 9.8%. One case of lymphogranuloma venereum was reported in Canada in 2004, 36 in 2005, and 96 between 2004 and 2011. Data on other equity indicators are limited or nonexistent.
Conclusions: Between 1991 and 2022, the incidence of chlamydia infection increased across Canada and, more particularly, in three provinces (Alberta, Saskatchewan, and Manitoba), which consistently reported chlamydia infection incidence rates 1.5 to 2 times the national average. Young people and females were the most severely affected groups. More complete and consistent epidemiological data, which would include incidence disaggregated by equity indicators, are crucial to addressing the increasing burden of chlamydia in Canada and, more particularly, the Prairie provinces.
{"title":"Increasing rates of Chlamydia trachomatis infection in Alberta, Saskatchewan, and Manitoba compared to Canada overall, between 1991 and 2022.","authors":"Maria Arango-Uribe, Rotem Keynan, Zipporah Gitau, Camilo Suarez-Ariza, Angela Copete, Mariana Herrera, Camila Oda, Ameeta E Singh, Stuart Skinner, Cara Spence, Lauren J MacKenzie, Ken Kasper, Laurie Ireland, Jared Bullard, David Alexander, Diana Marin, Lucelly Lopez, Margaret Haworth-Brockman, Yoav Keynan, Zulma Vanessa Rueda","doi":"10.1016/j.idnow.2026.105263","DOIUrl":"10.1016/j.idnow.2026.105263","url":null,"abstract":"<p><strong>Introduction: </strong>Chlamydia trachomatis is the most commonly encountered sexually transmitted infection. Our objective was to describe the evolution of chlamydia incidence rates in Alberta, Saskatchewan, and Manitoba as compared to Canada overall, from 1991 to 2022.</p><p><strong>Methods: </strong>We conducted an ecological study, collecting data on chlamydia infection from publicly available reports throughout Canada, laying special emphasis on Alberta, Saskatchewan, and Manitoba. As variables, we used: Chlamydia incidence rate per 100,000 inhabitants, stratified by sex, age group, ethnicity, province, and year.</p><p><strong>Results: </strong>In 1991, chlamydia incidence in Alberta (265.0/100,000), Saskatchewan (328.2/100,000), and Manitoba (410.2/100,000) largely exceeded the nationwide rate (164.0/100,000). Incidence subsequently increased dramatically, peaking between 2013 and 2019 (Canada overall: 335.1/100,000; Alberta: 399.9/100,000; Saskatchewan: 534.6/100,000; Manitoba: 604.5/100,000). Females aged 20-29 years accounted for 61.6% of the cases, while incidence in individuals aged 30-39 pronouncedly increased. Coinfection rates with Neisseria gonorrhoeae increased in Alberta (1998-2006) from 2.1% to 5.2% and decreased in Manitoba (2004-2012) from 14.8% to 9.8%. One case of lymphogranuloma venereum was reported in Canada in 2004, 36 in 2005, and 96 between 2004 and 2011. Data on other equity indicators are limited or nonexistent.</p><p><strong>Conclusions: </strong>Between 1991 and 2022, the incidence of chlamydia infection increased across Canada and, more particularly, in three provinces (Alberta, Saskatchewan, and Manitoba), which consistently reported chlamydia infection incidence rates 1.5 to 2 times the national average. Young people and females were the most severely affected groups. More complete and consistent epidemiological data, which would include incidence disaggregated by equity indicators, are crucial to addressing the increasing burden of chlamydia in Canada and, more particularly, the Prairie provinces.</p>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":" ","pages":"105263"},"PeriodicalIF":2.2,"publicationDate":"2026-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147463278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: This scoping review aims to map and synthesize the evidence on key challenges, facilitators, and recommendations related to the implementation and community acceptance of safe and dignified burials (SDBs) during outbreaks of Ebola disease (EBOD) or Marburg virus disease (MVD).
Introduction: SDBs are a critical public health intervention designed to reduce post-mortem transmission of EBOD and MVD-two contagious and often fatal diseases-while upholding cultural and religious practices. Despite their importance, challenges to implementation and acceptance have been documented, which may limit community uptake and operational effectiveness.
Inclusion criteria: This review will include original studies, peer-reviewed commentaries, and government, humanitarian, or international organization reports discussing challenges, facilitators, or recommendations related to SDB implementation or community acceptance. Sources published before 2014 or written in languages other than English or French will be excluded.
Methods: Searches will be conducted in Medline (Ovid), Web of Science, JSTOR, Global Health (Ovid), EMBASE (Ovid), and Social Sciences Abstracts (Ovid). Grey literature will be retrieved from key government and organization websites. Titles, abstracts, and full texts will be independently screened by two reviewers, and data will be extracted using a standardized tool. Data will be presented through a narrative summary and in tables.
目的：本范围审查旨在绘制和综合与埃博拉病（EBOD）或马尔堡病毒病（MVD）暴发期间实施和社区接受安全和有尊严的埋葬（sdb）相关的主要挑战、促进因素和建议的证据。简介：sdb是一项重要的公共卫生干预措施，旨在减少死后EBOD和mvd（两种传染性且往往致命的疾病）的传播，同时维护文化和宗教习俗。尽管它们很重要，但在实施和接受方面的挑战已被记录下来，这可能会限制社区的吸收和业务效率。纳入标准：本综述将包括原始研究、同行评议评论、政府、人道主义或国际组织报告，讨论与SDB实施或社区接受相关的挑战、促进因素或建议。2014年之前出版或以英语或法语以外的语言撰写的资料将被排除在外。方法：在Medline （Ovid）、Web of Science、JSTOR、Global Health （Ovid）、EMBASE （Ovid）和Social Sciences Abstracts （Ovid）中进行检索。灰色文献将从主要的政府和组织网站检索。标题、摘要和全文将由两位审稿人独立筛选，数据将使用标准化工具提取。数据将以叙述性摘要和表格的形式提出。
{"title":"Challenges and facilitators for the implementation of safe and dignified burials during Ebola and Marburg virus disease outbreaks: A scoping review protocol.","authors":"Jocelyne M Labonté, Celine Halim, Ilja Ormel, Doug Lau, Rajalakshmi Ravikumar, Elysée Nouvet","doi":"10.1016/j.idnow.2026.105265","DOIUrl":"10.1016/j.idnow.2026.105265","url":null,"abstract":"<p><strong>Objective: </strong>This scoping review aims to map and synthesize the evidence on key challenges, facilitators, and recommendations related to the implementation and community acceptance of safe and dignified burials (SDBs) during outbreaks of Ebola disease (EBOD) or Marburg virus disease (MVD).</p><p><strong>Introduction: </strong>SDBs are a critical public health intervention designed to reduce post-mortem transmission of EBOD and MVD-two contagious and often fatal diseases-while upholding cultural and religious practices. Despite their importance, challenges to implementation and acceptance have been documented, which may limit community uptake and operational effectiveness.</p><p><strong>Inclusion criteria: </strong>This review will include original studies, peer-reviewed commentaries, and government, humanitarian, or international organization reports discussing challenges, facilitators, or recommendations related to SDB implementation or community acceptance. Sources published before 2014 or written in languages other than English or French will be excluded.</p><p><strong>Methods: </strong>Searches will be conducted in Medline (Ovid), Web of Science, JSTOR, Global Health (Ovid), EMBASE (Ovid), and Social Sciences Abstracts (Ovid). Grey literature will be retrieved from key government and organization websites. Titles, abstracts, and full texts will be independently screened by two reviewers, and data will be extracted using a standardized tool. Data will be presented through a narrative summary and in tables.</p>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":" ","pages":"105265"},"PeriodicalIF":2.2,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147463275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2026-01-08DOI: 10.1016/j.idnow.2026.105245
Paul Le Turnier , Anissa Desmoulin , Sandrine Peugny , Loïc Epelboin , André Cabié , Mathieu Picardeau
{"title":"Leptospirosis in France: time to revise diagnostic algorithms and their reimbursement","authors":"Paul Le Turnier , Anissa Desmoulin , Sandrine Peugny , Loïc Epelboin , André Cabié , Mathieu Picardeau","doi":"10.1016/j.idnow.2026.105245","DOIUrl":"10.1016/j.idnow.2026.105245","url":null,"abstract":"","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"56 2","pages":"Article 105245"},"PeriodicalIF":2.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145922246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2026-01-27DOI: 10.1016/j.idnow.2026.105247
Paul Nicolas Vullierme , Tatiana Galperine , Nicolas Benech , Laurent Alric , Alexis Mosca , Anne-Christine Joly , Nathalie Kapel , Julien Scanzi , Cecilia Landman , Harry Sokol , Alexandre Bleibtreu
Background
Fecal microbiota transplantation (FMT) is validated for recurrent Clostridioides difficile infections but is increasingly considered for compassionate indications: steroid-refractory graft-versus-host disease (GVHD), multidrug-resistant organism (MDRO) eradication, severe inflammatory or infectious colitis. Evidence remains limited outside clinical trials.
Methods
Retrospective multicenter analysis of requests submitted to the French National Commission for compassionate FMT between 2019 and 2022. Approved cases were evaluated for feasibility, safety, and clinical outcomes.
Results
Among 67 requests, 54 were approved and 40 FMT procedures were performed. The main indications were severe steroid-resistant GVHD (35%), MDRO carriage (28%), and inflammatory/infectious colitis (12%). Overall success was 37.5%. The response rate for GVHD was 53% and 31% for MDRO eradication. Adverse events were mostly mild.
Conclusions
Compassionate FMT in France is feasible through a centralized process but shows variable efficacy depending on the indication. GVHD seems to be the most promising target, while MDRO eradication and colitis require further evaluation.
{"title":"Fecal microbiota transplantation in compassionate indications: French experience from 2019 to 2022","authors":"Paul Nicolas Vullierme , Tatiana Galperine , Nicolas Benech , Laurent Alric , Alexis Mosca , Anne-Christine Joly , Nathalie Kapel , Julien Scanzi , Cecilia Landman , Harry Sokol , Alexandre Bleibtreu","doi":"10.1016/j.idnow.2026.105247","DOIUrl":"10.1016/j.idnow.2026.105247","url":null,"abstract":"<div><h3>Background</h3><div>Fecal microbiota transplantation (FMT) is validated for recurrent <em>Clostridioides difficile</em> infections but is increasingly considered for compassionate indications: steroid-refractory graft-versus-host disease (GVHD), multidrug-resistant organism (MDRO) eradication, severe inflammatory or infectious colitis. Evidence remains limited outside clinical trials.</div></div><div><h3>Methods</h3><div>Retrospective multicenter analysis of requests submitted to the French National Commission for compassionate FMT between 2019 and 2022. Approved cases were evaluated for feasibility, safety, and clinical outcomes.</div></div><div><h3>Results</h3><div>Among 67 requests, 54 were approved and 40 FMT procedures were performed. The main indications were severe steroid-resistant GVHD (35%), MDRO carriage (28%), and inflammatory/infectious colitis (12%). Overall success was 37.5%. The response rate for GVHD was 53% and 31% for MDRO eradication. Adverse events were mostly mild.</div></div><div><h3>Conclusions</h3><div>Compassionate FMT in France is feasible through a centralized process but shows variable efficacy depending on the indication. GVHD seems to be the most promising target, while MDRO eradication and colitis require further evaluation.</div></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"56 2","pages":"Article 105247"},"PeriodicalIF":2.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146074132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2026-01-06DOI: 10.1016/j.idnow.2025.105243
Luc Dubreuil
A popular disk diffusion method was recently revisited by EUCAST (The European Committee on Antimicrobial Susceptibility Testing) and CA-SFM (Antibiogram committee of the French society of Microbiology), both of which encourage more laboratories to determine the susceptibility of anaerobes to antibiotics. Alternatives (gradient method or microdilution in liquid medium) to the reference method (dilution in agar) are proposed, but they are not without shortcomings. Despite significant progress, disk diffusion techniques remain a subject of debate. Our aims are to highlight the controversies concerning the choice of breakpoints as well as the major error and very major error rates observed using disk-diffusion methods. Based on the MIC distributions of five antibiotics obtained by the same reference method in Brucella agar, using a wide range of anaerobic species (which have been the subject of 12 publications), we re-interpreted the previous results according to the categorization criteria of the CLSI, CA-SFM (often close to each other), and also to the more recent EUCAST criteria. This enabled us to compare resistance rates based on the breakpoints proposed by these three institutions. When discrepancies in results appeared, modifications of some breakpoints were suggested.
{"title":"Antimicrobial susceptibility testing of anaerobes − Challenges and potential solutions for identifying breakpoints using the disk-diffusion method, based on re-analysis of a large panel of anaerobes","authors":"Luc Dubreuil","doi":"10.1016/j.idnow.2025.105243","DOIUrl":"10.1016/j.idnow.2025.105243","url":null,"abstract":"<div><div>A popular disk diffusion method was recently revisited by EUCAST (The European Committee on Antimicrobial Susceptibility Testing) and CA-SFM (Antibiogram committee of the French society of Microbiology), both of which encourage more laboratories to determine the susceptibility of anaerobes to antibiotics. Alternatives (gradient method or microdilution in liquid medium) to the reference method (dilution in agar) are proposed, but they are not without shortcomings. Despite significant progress, disk diffusion techniques remain a subject of debate. Our aims are to highlight the controversies concerning the choice of breakpoints as well as the major error and very major error rates observed using disk-diffusion methods. Based on the MIC distributions of five antibiotics obtained by the same reference method in Brucella agar, using a wide range of anaerobic species (which have been the subject of 12 publications), we re-interpreted the previous results according to the categorization criteria of the CLSI, CA-SFM (often close to each other), and also to the more recent EUCAST criteria. This enabled us to compare resistance rates based on the breakpoints proposed by these three institutions. When discrepancies in results appeared, modifications of some breakpoints were suggested.</div></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"56 2","pages":"Article 105243"},"PeriodicalIF":2.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145932882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2025-12-07DOI: 10.1016/j.idnow.2025.105226
Martin Trichet , Jean-Philippe Lanoix , Sylvain Diamantis , Emmanuel Forestier , Thibaut Fraisse , Julia Brochard-Libois , Carine Dokoula , Flora Ketz , Aurélia Henn , Alain Putot , Benoît Cazenave , Nicolas Baclet , Cédric De Villelongue , Nadège Lemarie , Claire Roubaud-Baudron , Gaëtan Gavazzi , Benoît De Wazières , Sébastien Gallien , Pauline Caraux-Paz , On behalf of GInGer
Introduction
The incidence of tuberculosis (TB) remains high in elderly adults in France. Immunosenescence and comorbidities challenge both diagnosis and treatment in this population. Recent data describing TB characteristics and outcomes in the elderlies are scarce. We aimed to describe clinical and microbiological features of TB in the elderly population and to identify factors associated with 2-year mortality.
Patients and methods
We conducted a retrospective multicenter study including patients aged ≥ 75 years who were diagnosed with TB between 2010 and 2020 across 18 centers. A multivariate analysis was used to identify factors independently associated with 2-year mortality.
Results
A total of 295 patients were included: mainly born in France (57%). Immunosuppression was rare (9.8%). Fever and cough were uncommon, while weight loss was the most frequent symptom (60.3%), significantly associated with diagnostic delays. Pulmonary TB was the predominant form (63.1%) with higher culture positivity observed in this group and in the oldest patients. Isoniazid resistance was rare (5.2%). Standard quadritherapy was the most common initial regimen and was not associated with higher rates of adverse events. At two-year follow-up, overall mortality was 31.3%. In multivariate analysis, mortality was significantly associated with severe renal failure, living in nursing home or long-term care facilities, and weight loss at presentation.
Conclusion
This study highlights the atypical presentation of TB in elderly adults and the continued use of standard quadritherapy despite low drug resistance. Weight loss, though nonspecific, appears to be the most prognostic symptom and is associated with delayed diagnosis and higher mortality.
{"title":"Characteristics of tuberculosis in elderly adults: A multicenter French study","authors":"Martin Trichet , Jean-Philippe Lanoix , Sylvain Diamantis , Emmanuel Forestier , Thibaut Fraisse , Julia Brochard-Libois , Carine Dokoula , Flora Ketz , Aurélia Henn , Alain Putot , Benoît Cazenave , Nicolas Baclet , Cédric De Villelongue , Nadège Lemarie , Claire Roubaud-Baudron , Gaëtan Gavazzi , Benoît De Wazières , Sébastien Gallien , Pauline Caraux-Paz , On behalf of GInGer","doi":"10.1016/j.idnow.2025.105226","DOIUrl":"10.1016/j.idnow.2025.105226","url":null,"abstract":"<div><h3>Introduction</h3><div>The incidence of tuberculosis (TB) remains high in elderly adults in France. Immunosenescence and comorbidities challenge both diagnosis and treatment in this population. Recent data describing TB characteristics and outcomes in the elderlies are scarce. We aimed to describe clinical and microbiological features of TB in the elderly population and to identify factors associated with 2-year mortality.</div></div><div><h3>Patients and methods</h3><div>We conducted a retrospective multicenter study including patients aged ≥ 75 years who were diagnosed with TB between 2010 and 2020 across 18 centers. A multivariate analysis was used to identify factors independently associated with 2-year mortality.</div></div><div><h3>Results</h3><div>A total of 295 patients were included: mainly born in France (57%). Immunosuppression was rare (9.8%). Fever and cough were uncommon, while weight loss was the most frequent symptom (60.3%), significantly associated with diagnostic delays. Pulmonary TB was the predominant form (63.1%) with higher culture positivity observed in this group and in the oldest patients. Isoniazid resistance was rare (5.2%). Standard quadritherapy was the most common initial regimen and was not associated with higher rates of adverse events. At two-year follow-up, overall mortality was 31.3%. In multivariate analysis, mortality was significantly associated with severe renal failure, living in nursing home or long-term care facilities, and weight loss at presentation.</div></div><div><h3>Conclusion</h3><div>This study highlights the atypical presentation of TB in elderly adults and the continued use of standard quadritherapy despite low drug resistance. Weight loss, though nonspecific, appears to be the most prognostic symptom and is associated with delayed diagnosis and higher mortality.</div></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"56 2","pages":"Article 105226"},"PeriodicalIF":2.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145714216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2025-12-04DOI: 10.1016/j.idnow.2025.105219
L. Cornu , V. Guyetand , C. Lambert , O. Lesens , L. Sauvat
Objectives
A serious game is a learning tool stimulating the participant’s interest through its original pedagogical approach. We aimed to assess the value of AntibioLab, a serious game designed to review antibiotic prescribing.
Material and methods
AntibioLab is a card game designed for common infectious diseases. A prospective single-center pilot study was performed with medical students. The AntibioLab group played two sessions one week apart, and the control group had to review the items corresponding to the serious game on their own between each questionnaire. Knowledge acquisition was assessed before the game, seven days after and at three months, with multiple-choice questions. A Likert-scale questionnaire was used to assess the game’s entertainment and pedagogical contribution. The primary endpoint (final score) was compared between groups using ANCOVA.
Results
Thirty-nine students (n = 21 AntibioLab group, n = 18 Control group) were included. The mean score at Day 0 was 10.8 ± 2.9 out of 20 without any significant difference between groups. At Month 3, the mean score was higher in the AntibioLab group (12.9 ± 3.0 and 10.5 ± 2.2 respectively, p = 0.03). In the longitudinal analysis, the score evolution between Day 0, Day 7 and Month 3 was not statistically different between the groups. In the AntibioLab group, students who responded to the questionnaire (n = 20) found the game fun, challenging and recommended it.
Conclusions
We highlighted the value of AntibioLab for consolidating knowledge in antibiotic therapy. Feedback from participants about the game’s benefits was excellent. AntibioLab could be an additional tool to review infectious diseases.
{"title":"Assessment of the educational and entertainment value of the serious antibiotic game: “AntibioLab”","authors":"L. Cornu , V. Guyetand , C. Lambert , O. Lesens , L. Sauvat","doi":"10.1016/j.idnow.2025.105219","DOIUrl":"10.1016/j.idnow.2025.105219","url":null,"abstract":"<div><h3>Objectives</h3><div>A serious game is a learning tool stimulating the participant’s interest through its original pedagogical approach. We aimed to assess the value of AntibioLab, a serious game designed to review antibiotic prescribing.</div></div><div><h3>Material and methods</h3><div>AntibioLab is a card game designed for common infectious diseases. A prospective single-center pilot study was performed with medical students. The AntibioLab group played two sessions one week apart, and the control group had to review the items corresponding to the serious game on their own between each questionnaire. Knowledge acquisition was assessed before the game, seven days after and at three months, with multiple-choice questions. A Likert-scale questionnaire was used to assess the game’s entertainment and pedagogical contribution. The primary endpoint (final score) was compared between groups using ANCOVA.</div></div><div><h3>Results</h3><div>Thirty-nine students (n = 21 AntibioLab group, n = 18 Control group) were included. The mean score at Day 0 was 10.8 ± 2.9 out of 20 without any significant difference between groups. At Month 3, the mean score was higher in the AntibioLab group (12.9 ± 3.0 and 10.5 ± 2.2 respectively, <em>p</em> = 0.03). In the longitudinal analysis, the score evolution between Day 0, Day 7 and Month 3 was not statistically different between the groups. In the AntibioLab group, students who responded to the questionnaire (n = 20) found the game fun, challenging and recommended it.</div></div><div><h3>Conclusions</h3><div>We highlighted the value of AntibioLab for consolidating knowledge in antibiotic therapy. Feedback from participants about the game’s benefits was excellent. AntibioLab could be an additional tool to review infectious diseases.</div></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"56 2","pages":"Article 105219"},"PeriodicalIF":2.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145695996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号